Researchers are a step closer to understanding how Parkinson’s disease develops and progresses.
Glycomics is an integral part of ABOzymes’ life-saving research and technology development.
Read some highlights from the 2022 Canadian Glycomics Symposium.
Findings show promise for developing potential new anti-inflammatory drugs and treatments for autoimmune diseases.
This collaboration combines Alectos’ expertise in small-molecule therapeutics with Biogen’s development capabilities in movement disorders.
In BIOTECanada’s Insights Magazine, GlycoNet Scientific Director Warren Wakarchuk writes about the importance of glycomics, opportunities to leverage glycomics, and Canadian glycomics expertise.
This investment will support state-of-the-art health research for Canada’s leading diseases, including cancer, diabetes, dementia, muscular dystrophy and universal donor blood.
GlycoNet researchers are studying a group of molecules that could provide insight into treating and monitoring neurodegenerative diseases.
Dr. Ratmir Derda’s achievements were recently recognized with an award at BioAlberta’s 2021 Awards Gala.
Dr. Lori Burrows shared how glycomics research is being used to develop a more effective vaccine against turberculosis.
Scientists discover a cellular mechanism that may yield insights into improving vaccines and better understanding cancer and autoimmune diseases.
GlycoNet received a NSERC PromoScience grant and partnered with the Centre for Mathematics, Science and Technology Education to develop resources that educators can use to teach the science behind vaccines and engage students in critical thinking.
Canadian Glycomics Network
E5-33 Gunning/Lemieux Chemistry Centre
University of Alberta, T6G 2G2
Tel: 780-492-6204
Fax: 780-492-4147
© CANADIAN GLYCOMICS NETWORK (GLYCONET). ALL RIGHTS RESERVED.